These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 25523561)

  • 1. New targeted therapies such as anti-adhesion molecules, anti-IL-12/23 and anti-Janus kinases are looking toward a more effective treatment of inflammatory bowel disease.
    Bravatà I; Fiorino G; Allocca M; Repici A; Danese S
    Scand J Gastroenterol; 2015 Jan; 50(1):113-20. PubMed ID: 25523561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrins and adhesion molecules as targets to treat inflammatory bowel disease.
    Bravatà I; Allocca M; Fiorino G; Danese S
    Curr Opin Pharmacol; 2015 Dec; 25():67-71. PubMed ID: 26687159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?
    Hindryckx P; Vande Casteele N; Novak G; Khanna R; D'Haens G; Sandborn WJ; Danese S; Jairath V; Feagan BG
    J Crohns Colitis; 2018 Jan; 12(1):105-119. PubMed ID: 28961959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment options for inflammatory bowel diseases.
    Verstockt B; Ferrante M; Vermeire S; Van Assche G
    J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy in inflammatory bowel disease.
    Loftus EV
    Gastroenterol Clin North Am; 2014 Sep; 43(3):xv-xvii. PubMed ID: 25110264
    [No Abstract]   [Full Text] [Related]  

  • 6. Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-γ-expressing Th1 cells and IL-17A/IL-22-expressing Th17 cells and respond to anti-IL-12/IL-23 antibody treatment.
    Tillack C; Ehmann LM; Friedrich M; Laubender RP; Papay P; Vogelsang H; Stallhofer J; Beigel F; Bedynek A; Wetzke M; Maier H; Koburger M; Wagner J; Glas J; Diegelmann J; Koglin S; Dombrowski Y; Schauber J; Wollenberg A; Brand S
    Gut; 2014 Apr; 63(4):567-77. PubMed ID: 23468464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Targeted Therapies for Inflammatory Bowel Disease.
    Coskun M; Vermeire S; Nielsen OH
    Trends Pharmacol Sci; 2017 Feb; 38(2):127-142. PubMed ID: 27916280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New choices, new challenges: Anti-TNF versus anti-integrin molecule therapy in IBD.
    van Langenberg DR
    J Gastroenterol Hepatol; 2016 Jun; 31 Suppl 1():10-1. PubMed ID: 26990680
    [No Abstract]   [Full Text] [Related]  

  • 9. Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.
    Verstockt B; Van Assche G; Vermeire S; Ferrante M
    Expert Opin Biol Ther; 2017 Jan; 17(1):31-47. PubMed ID: 27817215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New drug therapies on the horizon for IBD.
    Perrier C; Rutgeerts P
    Dig Dis; 2012; 30 Suppl 1():100-5. PubMed ID: 23075877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory Bowel Disease: New Therapeutic Options in the Post Anti-TNFα Era.
    Jiménez-Pérez M; Olmedo-Martín RV; Amo-Trillo VM; González-Gande R
    Curr Drug Metab; 2017; 18(7):666-679. PubMed ID: 28382862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic innovations in inflammatory bowel diseases.
    Vanhove W; Nys K; Vermeire S
    Clin Pharmacol Ther; 2016 Jan; 99(1):49-58. PubMed ID: 26509246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics.
    Katsanos KH; Papadakis KA
    Gut Liver; 2017 Jul; 11(4):455-463. PubMed ID: 28486793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New biological drugs in the treatment of inflammatory skin diseases].
    Mälkönen T
    Duodecim; 2014; 130(6):627-34. PubMed ID: 24724461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adalimumab for the treatment of inflammatory bowel disease.
    Wasan SK; Kane SV
    Expert Rev Gastroenterol Hepatol; 2011 Dec; 5(6):679-84. PubMed ID: 22017695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel therapeutic options in the inflammatory bowel disease world.
    Noble A; Baldassano R; Mamula P
    Dig Liver Dis; 2008 Jan; 40(1):22-31. PubMed ID: 17988966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy of inflammatory bowel disease: what to expect in the next decade.
    Leiman DA; Lichtenstein GR
    Curr Opin Gastroenterol; 2014 Jul; 30(4):385-90. PubMed ID: 24902037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.